ABRYSVO

(Respiratory Syncytial Virus Stabilized Prefusion F Subunit Vaccine)

Find ABRYSVO medical information:

ABRYSVO Quick Finder 

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

ABRYSVO Quick Finder 

The ABRYSVO Product Monograph is available here

ABRYSVO (Respiratory Syncytial Virus Stabilized Prefusion F Subunit Vaccine) is a bivalent vaccine indicated for:

  • Active immunization of pregnant individuals from 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.
  • Active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older.
  • Active immunization for the prevention of LRTD caused by RSV in individuals 18-59 years of age who are at increased risk for LRTD caused by RSV.

Resources

Didn’t find what you were looking for? 

Contact us

Call 1-800-463-6001*
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Medical Inquiry
Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product:
Canada Vigilance Program 
You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect.